Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1556-1568

  Rosenstock, Julio ^a   Brazg, Ronald ^b   Andryuk, Paula J ^c   Lu, Kaifeng ^c   Stein, Peter ^c  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b Rainier Clinical Research Center   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; PROINSULIN; SITAGLIPTIN;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; BACKACHE; BLURRED VISION; BODY WEIGHT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEATH; DEPRESSION; DIARRHEA; DIET; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; GOUT; HEALTH PROGRAM; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERSENSITIVITY; HYPOGLYCEMIA; INFLUENZA; INSULIN BLOOD LEVEL; LABORATORY TEST; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PATIENT COMPLIANCE; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; STATISTICAL ANALYSIS; SUICIDE ATTEMPT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING; WEIGHT GAIN;

AGED; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; PROTEASE INHIBITORS; PYRAZINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 33751557143     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.007     Document Type: Article

References (29)

1. Holst J.J., and Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287 (2004) E199-E206
2. Drucker D.J. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122 (2002) 531-544
3. Deacon C.F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53 (2004) 2181-2189
4. Deacon C.F. What do we know about the secretion and degradation of incretin hormones?. Regal Pept 128 (2005) 117-124
5. Deacon C.F., Ahren B., and Holst J.J. Inhibitors ofdipeptidyl peptidase IV. A novel approach for the prevention and treatment of type 2 diabetes?. Expert Opin lnvestig Drugs 137 (2004) 1091-1102
6. Holst J.J., and Deacon C.F. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol 4 (2004) 589-596
7. Ahren B., and Schmitz O. GLPT receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Norm Metab Res 36 (2004) 867-876
8. Kim D., Wang L., Beconi M., et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyraz in7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48 (2005) 141-151
9. Herman G.A., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects: Results from two randomized, double-blind, placebocontrolled studies with single oral doses. Clin Pharmacol Ther 78 (2005) 675-688
10. Bergman A.J., Stevens C., Zhou Y., et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28 (2006) 55-72
11. Herman GA, Bergam A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. Published online. doi:10.1210/jc.2006-1009.
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
13. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with met formin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865 [published correction appears in Lancet. 1998;352:1558]
14. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354: 602]. Lancet 352 (1998) 837-853
15. Saaddine J.B., Engelgau M.M., Beckles G.L., et al. A diabetes report card for the United States: Quality of care in the 1990s. Ann Intern Med 136 (2002) 565-574
16. Basu A., Shah P., Nielsen M., et al. Effects of type 2 diabetes on the regulation of hepatic glucose metabolism. J Investig Med 52 (2004) 366-374
17. Aronoff S., Rosenblatt S., Braithwaite S., et al., Pioglitazone 001 Study Group. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: A 6-month randomized placebo-controlled dose-response study. Diabetes Care 23 (2000) 1605-1611
18. Inzucchi S.E., Maggs D.G., Spollett G.R., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338 (1998) 7867-7872
19. Petersen K.F., Krssak M., Inzucchi S., et al. Mechanism of troglitazone action in type 2 diabetes. Diabetes 49 (2000) 827-831
20. Fonseca V., Rosenstock J., Patwardhan R., and Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 283 (2000) 1695-1702
21. Rosenstock J., Shen S.G., Gatlin M.R., and Foley J.E. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 25 (2002) 1529-1533
22. Rosenstock J., Goldstein B.J., Vinik Al., et al., RESULT Study Group. Effect of early addition of rosiglit azone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): The Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study. Diabetes Obes Metab 8 (2006) 49-57
23. Tura A., Pacini G., Kautzky-Willer A., et al. Basal and dynamic proinsulininsulin relationship to assess beta cell function during OGTT in metabolic disorders. Am J Physiol Endocrinol Metab 285 (2003) E155-E162
24. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
25. Katz A., Nambi S.S., Mather K., et al. Quantitative insulin sensitivity check index: A simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85 (2000) 2402-2410
26. American Diabetes Association. Standards of medical care for patients with diabetes mellitus [pub lished correction appears in Diabetes Care. 2003;26:972]. Diabetes Care 26 Suppl 1 (2003) S33-S50
27. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report ofthe National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
28. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein choles terol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
29. Hansen P.A., and Corbett J.A. Incretin hormones and insulin sensitivity. Trends Endocrinol Metab 16 (2005) 135-136